Small Biotech Innovation Act
- Sponsor
- Rep. Pfluger, August [R-TX-11]
- Committees
- Ways and Means Committee (primary)
- Last action
- Jun 4, 2025
Bottom line
The bill aims to protect small, R&D-focused biotech companies from Medicare drug price negotiations, potentially preserving incentives for innovation but also potentially increasing Medicare drug costs.
What it actually does
This bill amends the Social Security Act to create an exception for certain research and development-intensive small biotech manufacturers from the Medicare drug price negotiation program, starting in 2029. It defines what constitutes a 'small biotech manufacturer' and specifies the R&D investment thresholds required for the exception, which vary based on the number of qualifying single-source drugs a manufacturer has.
Proponents argue
Supporters argue that the current Medicare drug price negotiation program disproportionately harms small biotech companies, which rely heavily on initial drug revenues to fund future research and development. They contend that this exception is crucial to foster innovation, ensure a robust pipeline of new medicines, and prevent smaller companies from being acquired by larger pharmaceutical firms solely to avoid negotiation.
Opponents contend
Critics of such exceptions argue that they undermine the intent of the Medicare drug price negotiation program, which is to lower drug costs for seniors and taxpayers. They contend that creating carve-outs will lead to higher overall drug spending, reduce the program's effectiveness, and could incentivize companies to structure themselves to fit the exception criteria rather than genuinely focusing on R&D.
The bill is very short and easy to read, allowing for a quick understanding of its core provisions.
Section 2, amending Section 1192(d)(2) of the Social Security Act
Research and Development-Intensive Small Biotech Manufacturer Exception
This provision establishes that a 'negotiation eligible drug' will not include a qualifying single source drug from a 'research and development-intensive small biotech manufacturer' for initial price applicability years beginning in 2029. It defines a 'small biotech manufacturer' as one with 5 or fewer qualifying single source drugs and not owned by a foreign government. An R&D-intensive manufacturer must invest an 'applicable percent' of its net revenue (ranging from 30% to 70% based on the number of drugs) in R&D over the previous three years.
Supporters argue
Supporters argue this exception is vital for fostering innovation in the biotech sector, ensuring that smaller companies can reinvest profits into developing new, life-saving drugs without the immediate pressure of price negotiations. They believe it will prevent a 'valley of death' for promising therapies.
Critics contend
Opponents contend that this exception creates a loophole that could be exploited, leading to higher drug costs for Medicare and its beneficiaries. They argue it weakens the overall negotiation program and that all manufacturers, regardless of size, should contribute to drug affordability.
Tradeoffs
The provision navigates the tension between incentivizing pharmaceutical innovation by protecting smaller R&D-focused companies and the goal of reducing drug costs for Medicare. It seeks to balance the need for new drug development with the imperative of affordability.
The 'applicable percent' of net revenue a small biotech manufacturer must invest in R&D to qualify for the exception varies based on the number of qualifying single source drugs it has: 30% for 1 drug, 40% for 2, 50% for 3, 60% for 4, and 70% for 5 drugs.
Section 2, amending Section 1192(d)(2)(D)(ii)(I)
Why it matters:This is standard legislative practice for defining thresholds and criteria within a complex definition.
Case for: Proponents argue this tiered structure appropriately scales the R&D investment requirement, recognizing that companies with more drugs might have a larger revenue base and thus can afford a higher R&D percentage while still protecting smaller, nascent companies.
Case against: Critics might argue that such a tiered system adds complexity and could create perverse incentives for manufacturers to manage their drug portfolio to stay within lower-tier R&D requirements or to avoid exceeding certain drug counts.
Estimated impact: This specific scaling mechanism could influence how many small biotech manufacturers qualify for the exception and the total R&D investment required from them.
A drug will lose its exception status if the manufacturer is acquired after 2029 by another manufacturer that does not meet the definition of a research and development-intensive small biotech manufacturer, effective the plan year following acquisition.
Section 2, amending Section 1192(d)(2)(D)(iii)
Why it matters:This is a standard anti-abuse or anti-loophole provision, often placed as a condition or limitation.
Case for: Proponents argue this prevents larger pharmaceutical companies from acquiring small biotechs solely to shield their drugs from negotiation, ensuring the exception benefits genuine small innovators.
Case against: Some might argue it could complicate mergers and acquisitions, potentially limiting exit opportunities for small biotechs or making them less attractive targets for larger companies, which could indirectly hinder innovation.
Estimated impact: This clause aims to prevent larger companies from circumventing negotiation rules through strategic acquisitions, thereby preserving the integrity of the negotiation program for drugs developed by larger entities.
A 'small biotech manufacturer' must not be owned by, controlled by, or subject to the jurisdiction or direction of a government of a foreign country that is a 'covered nation' (as defined in 10 U.S.C. 4872(f)).
Section 2, amending Section 1192(d)(2)(D)(ii)(II)(bb)
Why it matters:This is a national security or economic protection clause, often included in legislation to prevent foreign adversaries from benefiting from U.S. incentives.
Case for: Proponents argue this ensures that the benefits of the exception are directed towards domestic or allied innovation, preventing 'covered nations' from gaining an unfair advantage or exploiting U.S. healthcare spending.
Case against: Some might argue that it could limit global collaboration in biotech or exclude potentially innovative companies based on geopolitical considerations rather than scientific merit, though this argument is less common for 'covered nations'.
Estimated impact: This provision restricts the eligibility of manufacturers tied to specific foreign governments, aligning the bill with broader national security concerns.